Quadrant Capital Group LLC Cuts Stock Holdings in Merck & Co., Inc. (NYSE:MRK)

Quadrant Capital Group LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 1.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 32,926 shares of the company’s stock after selling 427 shares during the quarter. Quadrant Capital Group LLC’s holdings in Merck & Co., Inc. were worth $3,590,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of MRK. NTV Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 0.3% in the 4th quarter. NTV Asset Management LLC now owns 26,534 shares of the company’s stock worth $2,893,000 after purchasing an additional 80 shares in the last quarter. SRS Capital Advisors Inc. lifted its position in shares of Merck & Co., Inc. by 1.6% during the 4th quarter. SRS Capital Advisors Inc. now owns 5,037 shares of the company’s stock valued at $549,000 after buying an additional 81 shares in the last quarter. Endowment Wealth Management Inc. grew its stake in shares of Merck & Co., Inc. by 3.2% during the 4th quarter. Endowment Wealth Management Inc. now owns 2,637 shares of the company’s stock valued at $288,000 after acquiring an additional 81 shares during the period. Onyx Bridge Wealth Group LLC raised its stake in Merck & Co., Inc. by 0.4% during the 4th quarter. Onyx Bridge Wealth Group LLC now owns 19,166 shares of the company’s stock worth $2,089,000 after acquiring an additional 83 shares during the period. Finally, Ascent Wealth Partners LLC lifted its holdings in Merck & Co., Inc. by 0.5% during the fourth quarter. Ascent Wealth Partners LLC now owns 16,579 shares of the company’s stock valued at $1,807,000 after purchasing an additional 89 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors.

Merck & Co., Inc. Trading Down 0.0 %

NYSE MRK traded down $0.05 during trading hours on Friday, hitting $130.83. 2,854,425 shares of the company were exchanged, compared to its average volume of 8,043,461. Merck & Co., Inc. has a 52 week low of $99.14 and a 52 week high of $133.10. The company has a quick ratio of 0.99, a current ratio of 1.25 and a debt-to-equity ratio of 0.77. The stock has a 50-day moving average price of $127.12 and a 200 day moving average price of $118.42. The stock has a market cap of $331.37 billion, a PE ratio of 145.43, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.40 EPS. Analysts forecast that Merck & Co., Inc. will post 8.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Berenberg Bank increased their price target on Merck & Co., Inc. from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Truist Financial lifted their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Barclays upped their price target on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, February 2nd. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. Finally, Societe Generale lowered shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research report on Monday, March 11th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $131.33.

About Merck & Co., Inc.

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.